Eli Lilly and Company revised earnings guidance for the year 2021. For the period, the company has updated certain elements of its 2021 financial guidance on a reported basis. Earnings per share for 2021 are now expected to be in the range of $7.10 to $7.75 compared to prior guidance of $7.25 to $7.90 on a reported basis and are still expected to be in the range of $7.75 to $8.40 on a non-GAAP basis. The company still anticipates 2021 revenue between $26.5 billion and $28.0 billion, including an estimated $1 billion to $2 billion of revenue from COVID-19 therapies.